Campath-1H
Hurler Syndrome
Masonic Cancer Center, University of Minnesotamonoclonal_antibodyPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Hurler Syndrome cohort.
View all 14 →
Same molecule, other indications
Campath-1H is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →